Spain's plans to consolidate its IPT assessment arrangements faced delays due to legal challenges, reflecting difficulties in changing infrastructure.

The intention was to introduce a formal economic analysis combined with clinical appraisals, similar to other established models. However, despite setbacks, there remains a shift towards emphasizing cost-effectiveness data and exploring innovative contracting, like risk-sharing outcome-based agreements, for medicines in Spain.

An extract from September’s EU/UK/Asia session of Verpora's webinar series exploring the latest trends and policies surrounding Global Innovative Contracting, in EU, UK and Asia regions.

Register here for future events

Speakers

Omar Ali
Head of Payers, Verpora
LinkedIn

Adam Meads
Head of Research & Analytics, Verpora
LinkedIn